Samsung Bio, Moderna mRNA Vaccine Contract for Contract Manufacturing... "Immediate Start of Technology Transfer"

[Asia Economy Reporter Seo So-jung] Samsung Biologics announced on the 23rd that it signed a contract with Moderna on the 22nd for the contract manufacturing of finished products of the COVID-19 messenger ribonucleic acid (mRNA) vaccine.

According to this contract, Samsung Biologics will immediately begin technology transfer of the Moderna vaccine and plans to start aseptic filling, labeling, and packaging of hundreds of millions of doses of the vaccine for markets outside the United States from the third quarter.

John Rim, CEO of Samsung Biologics, stated, "The Moderna vaccine is the most important vaccine for people worldwide fighting against COVID-19," and emphasized, "We have established a rapid production schedule to enable commercial supply by early the second half of this year in response to the urgent global demand for vaccines."

Juan Andres, Moderna’s Chief Technology and Quality Officer (CTO & QO), said, "We are very pleased to establish a finished product manufacturing partnership with Samsung Biologics," and added, "We expect this contract to help us continue expanding our production capacity outside the United States."

This content was produced with the assistance of AI translation services.